



IDT Biologika With New Dual Leadership: Dr. Ulrich Valley Appointed Second Managing Director

Dessau-Roßlau, 01 October 2022 - IDT Biologika is taking the next step in its growth strategy by expanding its management team to a dual leadership. Effective October 1, 2022, Dr. Ulrich Valley will become Chief Operations Officer (COO) and second Managing Director of IDT Biologika.

Dr. Ulrich Valley was previously Senior Vice President of Operations and Site Manager of KBI Biopharma in Geneva, Switzerland and managed KBI's site in Leuven, Belgium. He has many years of experience in the pharmaceutical industry and has held various management positions, including at Novartis and Sandoz, with a focus on Technical Operations, Supply Chain and Development.

Dr. Ulrich Valley will lead IDT together with Dr. Jürgen Betzing, who is Chairman of the Executive Board.

"In the past two years, IDT has primarily established itself on the market as a reliable vaccine manufacturer, thus laying the foundation for the next strategic milestones. It is now important to focus more on our services in the field of cell and gene therapy or process development and production of clinical trials materials. Due to the growing business activities, it is only logical to also place the management on a broader basis," said Dr. Jürgen Betzing.

"In Ulrich Valley, we have been able to engage a highly qualified managing director for this responsible task, who brings with him extensive knowledge in the field of manufacturing and is familiar with the structures of globally operating pharmaceutical companies. I am delighted that we can continue our growth strategy together with Ulrich Valley," emphasizes Dr. Jürgen Betzing.

1,700 characters (including spaces)

Images



[2022-10-01 Dr_Ulrich_Valley.jpg]

Dr. Ulrich Valley, Chief Operations Officer (COO) und second Managing Director IDT Biologika



About IDT Biologika

IDT Biologika is an innovative biotech company with a successful history dating back 100 years. On the basis of modern technologies and high levels of expertise, IDT supports customers in the development and manufacture of innovative virus vaccines, gene and immune therapy products as well as biologics employed worldwide as protection against diseases. IDT Biologika employs approximately 1,650 people. German sites are the BioPharmaPark in Dessau-Roßlau and Magdeburg. In the US, the IDT Corporation has a manufacturing site for clinical test samples in Rockville, Maryland.

Website: www.idt-biologika.com

Contact IDT Biologika

Corinna Meisel

Corporate Communications

M +49 (0)173 9249671

corinna.meisel@idt-biologika.de

IDT Biologika GmbH | Am Pharmapark | D-06861 Dessau-Roßlau, Germany